• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

IRINOTECAN HYDROCHLORIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • IRINOTECAN HYDROCHLORIDE chembl:CHEMBL3989514 Approved

    Alternate Names:

    IRINOTECAN MONOHYDROCHLORIDE TRIHYDRATE
    CAMPTOSAR
    DQ-2805
    CPT-11
    CAMPTO
    IRINOTECAN HYDROCHLORIDE ANHYDROUS
    U-101440E
    IRINOTECAN HYDROCHLORIDE HYDRATE
    IRINOTECAN HCL
    IRINOTECAN HYDROCHLORIDE TRIHYDRATE
    ONIVYDE

    Drug Info:

    (0 More Sources)

    Publications:

    Okamoto et al., 2002, O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives., Jpn. J. Cancer Res.
    Minderman et al., 2005, In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells., Mol. Cancer Ther.
    Chu et al., 1999, Active efflux of CPT-11 and its metabolites in human KB-derived cell lines., J. Pharmacol. Exp. Ther.
    Okamura et al., 2000, NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy., Int. J. Oncol.
    Xiang et al., 2002, Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors., Oncogene
    Koizumi et al., 2005, Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells., Int. J. Oncol.
    Romero et al., 2006, Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients., Oncol. Rep.
  • IRINOTECAN HYDROCHLORIDE   CDKN1A

    Interaction Score: 0.9

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12032863


    Sources:
    NCI

  • IRINOTECAN HYDROCHLORIDE   GSTM1

    Interaction Score: 0.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16865249


    Sources:
    NCI

  • IRINOTECAN HYDROCHLORIDE   MGMT

    Interaction Score: 0.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11802813


    Sources:
    NCI

  • IRINOTECAN HYDROCHLORIDE   BIRC5

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15956246


    Sources:
    NCI

  • IRINOTECAN HYDROCHLORIDE   ABCC1

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9918583


    Sources:
    NCI

  • IRINOTECAN HYDROCHLORIDE   GSTP1

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10639573


    Sources:
    NCI

  • IRINOTECAN HYDROCHLORIDE   PIK3CA

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15809721


    Sources:
    NCI

  • NCI: CPT-11

    • Version: 14-September-2017

    Alternate Names:
    C1381 NCI drug code

    Drug Info:

    Publications:
    Okamoto et al., 2002, O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives., Jpn. J. Cancer Res.
    Okamura et al., 2000, NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy., Int. J. Oncol.
    Romero et al., 2006, Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients., Oncol. Rep.

  • ChemblDrugs: chembl:CHEMBL3989514

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21